Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2014; 20(7): 1746-1755
Published online Feb 21, 2014. doi: 10.3748/wjg.v20.i7.1746
Table 1 Use of dietary supplement in the prevention of hepatic steatosis
Oil sourceOil fatty acid composition (%)Experimental designResultsRef.
KrillC14:0 C16:0 C18:0 C18:1 C18:2 C18:3 C20:5 C22:5 C22:62.5 18.2 2.8 25.8 54.4 4.9 5.3 2.3 3.0C57BL/6 mice fed for 8 wk with a high-fat diet containing 1.25%-5% krill oil↓ Hepatomegaly ↓ Hepatic steatosis ↓De novo lipogenesis ↓ Blood glucoseTandy et al[50]
Wistar rats fed for 6 wk with a diet containing 2.5% krill oil↓ Hepatic steatosis ↓De novo lipogenesis ↓ Haematic triglycerides ↓ Haematic cholesterolFerramosca et al[43]
Sprague-Dawley rats fed for 12 wk with a high-fat diet containing 2.5% krill oil↓ Hepatic steatosis ↓De novo lipogenesis ↑ Fatty acid oxidation ↓ Mitochondrial uncoupling ↓ Haematic glucose ↓ Haematic insulin ↓ Haematic triglyceridesFerramosca et al[42]
Pine nutC16:0 C18:0 C18:1 C18:2 C18:3 C18:3 (5,9,12)8.0 2.2 23.2 51.1 2.1 8.8Mice fed for 8 wk with a diet containing 7.5% pine nut oil↓ Liver weight ↓ Hepatic steatosis ↓De novo lipogenesis ↓ Haematic triglycerides ↓ Haematic cholesterolFerramosca et al[40]